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HISTOPATHOLOGICAL DETERMINANTS OF
SURVIVAL IN RESECTED CASES OF PANCREAS
CANCER
S.T.BROWER, R.M.NEWMAN, D.PERTSEMLIDIS, I.KREEL and
A.H.AUFSES, Jr.
Department of Surgery, Division of Surgical Oncology, Mount Sinai Medical
Center, New York, New York, USA
We have examined the histopathological factors affecting the degree of local spread, regional lymph
node (RLN) metastases, and overall survival (O.S.) in a group of 39 cases of resected carcinoma of the
exocrine pancreas. Although the mean O.S. for the group was 14.3 months, resected patients without
RLN involvement had a mean survival of 24 months. In contrast the mean O.S. rate was 8 months for
patients with RLNs involved. Size, tumor location, and histological grade were compared to RLN
involvement and O.S. The mean size of primary tumor did not differ significantly between patients with
or without RLN’s (r.1 versus 4.6cms). However, 7 or 8 T1 tumors were <4cm and 35% of tumors < 4cm
were T1 lesions. In contrast, only of 17 tumors (6%) >4cm was T1. Histological grade was correlated
with nodal status and O.S. There was a significant difference between histological grade and the
presence of metastatic lymph nodes (G1, 37% positive, G2-4.50% positive). Patients with well
differentiated tumors had a mean survival of 21 months compared to a mean survival of 10 months for
less differentiated tumors (p< 0.05). This difference was even more significant when stratified for nodal
status. The patients with well differentiated tumors and no RLN involvement had a mean survival of
32.5 months compared to 8.6 months for well differentiated tumors with RLN involvement. In
summary, we have shown that size, histological grade, and local spread predict for nodal status.
However, specific patient subsets (G1, node negative) may exhibit an excellent survival when curative
pancreas resection is successful.
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INTRODUCTION
Pancreas cancer is the fourth most common cause of cancer related mortality in the
United States12, with an overall survival rate of 0-5%. Despite advances in
diagnostic technology, most patients are identified by clinical presentation, and
associated local and distant spread25. Even in patients wtih localized disease, mean
survival remains less than 16 months after attempted curative resection3’67. Surgical
resection, however, remains the only chance for long term survival3’67.
Certain pathological characteristics of the pancreatic cancer seem to be import-
ant in predicting outcome81. The degree of local spread of the primary tumor and
status of the regional lymph nodes have been recognized as important determinants
of staging by the American Joint Committee on Cancerv2. By understanding how
characteristics of pancreatic malignancies effect the degree of local spread and
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nodal involvement, subsets of patients may be identified that would be more
amenable to attempted curative resection.
We retrospectively reviewed pathological data from resected cases of pancreatic
cancer with particular attention to the extent of loco-regional invasion, histopatho-
logical characteristics of the primary tumor, lymphatic invasion, size, and, differen-
tiation. We have attempted to analyze those factors that may have influenced
postoperative survival.
MATERIALS AND METHODS
Fifty-four cases of attempted curative resection for pancreatic neoplasms were
retrospectively reviewed. Surgery for these patients was performed at The Mount
Sinai Medical Center from 1985 to 1990. The pathological material from all patients
was reviewed and confirmed the diagnosis of malignant pancreatic neoplasm (duct
cell adenocarcinoma n=37). Islet cell tumors (11 cases) and mucinous-
cystadenocarcinomas (6 cases) were excluded). The study group consisted of 54%
males and 46% females, with an average age at operation of 63 years.
American Joint Committee on Cancer (AJCC) staging criteria were used to
categorize patients intoTNM stages as follows; Degree of local spread is delineated
by: T1; tumors limited to the pancreas, T2; tumors directly spread to peripancreatic
tissue, bile duct, or duodenum, and T3; tumors directly spread to the stomach,
colon, spleen, or adjacent large vessels. Regional Lymph node status is categorized
by: NO; nodes uninvolved and N1; nodes involved". Size refers to the largest
dimension of the primary tumor as reported by surgical pathology. Histologic grade
of the primary tumor was divided into two groups; well differentiated (gl), and less
well differentiated (G2-G4) including moderately, poorly, and undifferentiated
tumors.
The types of surgery performed included pancreaticoduodenectomies (Whipple
procedure n=22), total pancreatectomies (n= 11), and distal pancreatectomies
(n 4). Although clinically involved as well as clinically uninvolved peripancreatic
and regional nodes were included in the resections, no attempt was made to
perform a radical regional lymphadenectomy as advocated by other authors7’1112.
An average of 9.5 major pancreatic resections (pancreaticoduodenectomy and total
pancreatectomy) were performed each year. Although the procedures were per-
formed by a number of surgeons, the maximum average number of major
resections performed by an individual surgeon was 4.5 in each year. The perfor-
mance of total pancreatectomy followed a bell-shaped distribution over the five
year period with the maximum number of 4 performed per year being reduced to 2
since 1988.
Adjuvant chemotherapy and radiation therapy were administered according to
various experimental protocols. Although no standardized treatment was univer-
sally administered, the total number of patients receiving adjuvant chemotherapy
after surgery was 11. Five patients received regional radiation therapy after
attempted curative resection.
Actuarial survival was calculated using Kaplan-Meier plots13. A multivariate Cox
proportional hazards model was used to determine which independent factors
jointly predicted long term survivalTM.PANCREATIC CANCER 3
RESULTS
Areas of Local Spread in Relation to Position of Primary Tumor
Of the thirty seven patients, eight had tumors limited to the pancreas (T1),
twenty-one were designated T2, and eight had other organ involvement or large
vessel encasement (T3). Any one primary tumor may have spread to several
loco-regional areas (Table 1). The areas of local spread are logically dictated by the
position of the primary tumor.
As seen in Table 1, the most direct sites of local spread were in the peripancreatic
tissues, bile duct and duodenum. The incidence of peripancreatic tissue involve-
ment was approximately equal for tumors located in the head versus the body and
tail. 50% of tumors in the head of the pancreas that involved the peripancreatic
tissue had no invasion of the duodenum or the bile duct.
Invasion of adjacent large vessels was seen in only three resected specimens.
Interestingly, all of the resections for cure which included local spread to adjacent
large vessels were tumors located in the pancreatic head. The most common sites of
contiguous organ involvement included the stomach, spleen and colon. Direct
invasion of the transverse colon and transverse mesocolon was noted in one each of
the body and tail lesions. Three cases (8%) demonstrated direct invasion of the
stomach. Similarly three lesions were found to invade the splenic hilum.
Table 1 Areas of local spread in relation to position of primary tumor. The tumors were divided into
TI, T2, T spread and analyzed by position of primary tumor. See Materials and Methods section for
designation of T stage
Degree of Spread Head Body Tail
T1
Limited to Pancreas 7
T2
Peripancreatic Tissues 10 4 4
Duodenum 4
Bile Duct 7
T3
Stomach
Spleen 2
Colon
Adjacent Large Vessels 3
Table 2 Local spread and position of primary pancreatic tumor
TNM Classification
Head (n=24) 7 (24%) 13 (54%) 4
Body (n=5) 0 4 (80%)
Tail (n= 8) (13%) 4 (20%) 3
Total 8 21 8
(17070)
(2070)
(3770)4 S.T. BROWER ET AL.
Of 13 patients with T2 carcinoma of the head of the pancreas, 12 tumors involved
the bile duct, duodenum or both. Ten of the 13 patients had peripancreatic direct
invasion of the retroperitoneum.
Table 2 demonstrates that 52% of patients had T degree of local spread. Of the
tumors limited to the pancreas alone (T1), 88% of them were in the head.
However, only 24% of the total lesions of the head were confined within the
pancreatic capsule. In contrast, only 1 of 13 body and tail lesions was contained
within the pancreas. Tumors of the tail had the largest percentage (37%) of
contiguous organ spread (T).
The size of the primary tumor correlated with the percentage of the tumors that
were localized. This effect of size on local spread is seen in Table 3. As one might
expect, 7 of 8 (88%) T1 tumors were smaller than 4cm. In contrast T3 tumors tended
to be larger (> 4cm) with 6 of 8 (75%) tumors falling into this category. Small
tumors, however, did not protect against contiguous loco-regional spread to bile
duct, duodenum or peripancreatic tissues. The T tumors were equally as likely to
be less than or greater than 4 cm (55% and 59% respectively). When the data
comparing size and degree of local spread were stratified for location of the primary
tumor, the degree of local spread remained similar to the group as a whole (data
not shown). Therefore, it seems that size, as a predictor of local spread, is similar
for different regions of the pancreas.
Table 4 analyzes the relationship of histological grade and degree of local spread.
Sixteen tumors were well differentiated neoplasms as compared to 21 tumors with
moderately to poorly differentiated histology. The degree of differentiation was a
significant factor in predicting which tumors were limited to the pancreas. 31% of
the well differentiated tumors were T1 lesions whereas only 14% of the less well
differentiated group were contained within the pancreas (p< .05). In contract, the
T2 lesions demonstrated histologies that were more undifferentiated in 67% of the
specimens (p< .005). Patients with T3 local spread were equally as likely to have
well differentiated versus less well differentiated tumors. Although the well
differentiated tumors were equally distributed among the different types of local
spread (T1, Y2, T3), the less well differentiated pancreatic carcinomas were more
often seen with peripancreatic spread.
Table 3 The effect of size of primary tumor on degree of local spread
TNM Classification
Size n T1 T2 T3
<4cm 20 7 (35%) 11 (55%) 2
>4cm 17 (6%) 10 (59%) 6
(10%)
(35%)
Table 4 Histologic grade and degree of local spread
TNM Classification
Histologic grade n T1 T2 T3
Well Differentiated (G1) 16 5 (31%) 7 (44%) 4
Less Well Differentiated 21 3 (14%) 14 (67%) 4
(Grades 2, 3 & 4)
(25%)
(19%)PANCREATIC CANCER 5
Table 5 examines the effect of size and grade on the degree of local spread with
tumors stratified for _< 4 cm versus tumors > 4 cm). For lesions in the small tumor
size group, a statistically significant difference was seen when comparing histologi-
cal grade and the degree of local spread. Of the 20 patients identified with small
tumors, 10 were less well differentiated. The well differentiated group had 50% of
tumors limited to the pancreas at the time of resection whereas only 20% of the less
well differentiated group were so localized (p< .005).
Among the large tumor group, only one tumor %9%0 that was less well
differentiated was also confined to the substance of the pancreas. Therefore it
would seem that in the larger tumor size group that the distribution for local spread
seemed to follow what would be expected on the basis of size alone without regard
to differentiation. This is in contrast to the smaller sized tumors. When examined
for size alone 35% (7 of 20) tumors < 4 cm were limited to the pancreas. This is
contrasted to the finding of 50% of well differentiated tumors -<4cm which were
limited to the pancreas.
The influence of local spread on overall survival is seen in Table 6. As seen,
patients with tumors limited to the pancreas demonstrated superior survival when
compared to tumors with peripancreatic (p<0.05) or contiguous organ spread
(p< .001). There is an obvious trend of decreased survival with increasing degree of
local spread.
This difference in survival is similarly seen in the actuarial curve of Figure 1. The
differences in actuarial survival are statistically significant when T tumors are
compared to T2 and T3 cancers. At 24 and 36 months, the actuarial survival of TI
Table 5 The effect of size and grade on degree of local spread. The tumors were stratified for size <4cm
or >4cm and the T stage identified. The asterisk indicates a comparison between groups with ap value <0.05
TNM Classification
Size Number T1 T2 T3
<4cm (n 20)
Well Differentiated (G1) 10 4
Less Well Differentiated 10 7
(G2, 3 & 4)
>4cm (n 17)
Well Differentiated (G 1) 6 3 3
Less Well Differentiated 11 7 3
(G2, 3 & 4)
p=0.05
Table 6 Overall survival and degree of local spread. The mean overall survival was noted for three groups
TI, T2, T3
Degree of Spread Overall Survival (months)
T1 21.0
T2 15.8
T3 5.4
p <0.05 for groups T1, T2; p <0.01 for groups T2, T3; p <0.001 for groups T1, T36 S. T. BROWER ET AL.
100%
OO%
401o
0%
MONTHS
Figure 1 Actuarial survival as a function of T stage. [] T1, ., T 0 T3.
patients was 31%. This is contrasted to diminished survival of 9% and 5% for T2
and T3 cancers.
Regional Lymph Node Involvement
Of the thirty-seven patients resected for cure, pathologic data for metastatic
regional lymph node involvement was available on 35 patients (Table 7). Sixteen
patients (45%) were free of nodal involvement and 19 patients (55%) had at least
one positive lymph node. We had previously demonstrated that the degree of local
spread could influence survival following curative resection (Table 6, Figure 1). We
next examined whether this effect was due to the status of regional lymph nodes.
As shown in Table 7, among the various degrees of local spread, only T1 tumors
(limited to the pancreas) showed any significant difference in favor of negative
regional lymph node status. About 2/3 of the patients with tumors confined to the
pancreas were free of regional lymph node involvement. This was in sharp contrast
for T or T3 cancers where 60% of the tumors were metastatic to the regional lymph
nodes.
Table 8 examines the sites of local spread as a predictor for regional lymph node
involvement. Other than for T1 tumors limited to the pancreas in which 63% of the
patients had no metastatic lymph nodes, all other sites of contiguous spread failed
to differentiate between positive or negative lymph nodes. For example, the 17
patients who demonstrated peripancreatic retroperitoneal involvement were
equally as likely to have uninvolved or involved regional lymph nodes. Similarly,PANCREATIC CANCER 7
Table 7 Degree of local spread and regional lymph node (RLN) status
TNM Tumor Classification No RLN Involvement RLNs Involved
T1 (n=8) 5 (6370) 3 (37070)
T2 (n 20) 8 (40%) 12 (60%)
T3 (n= 7) 3 (43070) 4 (57070)
p <0.05 for T1 vs T2 or T3.
Table 8 Sites of local spread and regional lymph node involvement
Regional Lymph Regional Lymph
Degree of Spread Nodes Not Involved Nodes Involved p Value
T1
Limited to Pancreas n=8 5 (63%) 3 (37070) <0.05
T2
Peripancreatic Tissue n= 17 8 (47%) 9 (53%) ns
Duodenum & Bile Duct n= 12 5 (42%) 7 (58070) ns
T3
Stomach n 2 (50%) (50070) ns
Spleen n 2 (50070) (50070) ns
Colon n (10007o) 0 ns
Adjacent Large Vessels n= 3 (33070) 2 (67070) ns
Table 9 Histologic grade and nodal status
Grade No RLN Involvement RLNs lnvolved
G1 9 (63070) 6 (37070)
G2-4 13 (50%) 13 (50070)
the 12 patients demonstrating direct extension to the duodenum or bile duct, did
not predict the presence of regional lymph node involvement.
As seen in Table 9, the degree of differentiation of the primary tumor was a
significant determinant of nodal status in the well differentiated group. As pre-
viously stated, only G1 tumors were different when examined for regional lymph
node involvement (63% versus 37% respectively). The more undifferentiated
tumors were equally as likely to have uninvolved or metastatic nodes present as
50% of patients with G2-4 histology were free of positive lymph nodes. Among
patients with lesions of the head, an equal number had positive nodal involvement
or the absence of regional lymph nodes (RLNs). Twelve of 24 patients with tumors
confined to the head of the pancreas were without evidence of regional lymph
nodes. For the 11 patients with tumors within the body and tail of the pancreas 7 of
11 (63%) contained positive lymph nodes.
With respect to the size of tumors and the relationship on nodal status, small
tumors -<4cm were just as likely to have node free disease or RLNs involved.
However, for tumors >4 cm, RLNs were twice as likely to have microscopic
involvement than to be free of disease.8 S. T. BROWER ET AL.
Survival
The operative mortality for the entire group was 5.8% (2/37 patients). This figure
compares favorably with other reported perioperative mortality rates for maior
pancreatic resection6’8’15v. Ths mean overall survival for the group was 14.3 months
following resection (Table 10). When the group was further stratified by the degree
of local spread, T patients had a median survival of 24.5 months. This was
statistically different from the median survival of T2 (8.3 months) and T3 (7.8
months).
Survival as a function of regional lymph node status was next examined. As
demonstrated in Table 10 the overall survival for patients with negative lymph
nodes was 23.5 months. This is in contrast to the overall survival for patients with
positive lymph nodes which was 7.4 months (p< .05). Figure 2 demonstrates the
overall survival for node negative and node positive patients at 36 months. 31% of
the node negative pancreatic cancer patients were alive at 36 months. This is in
sharp contrast to 5% of patients alive with positive lymph nodes. The survival by
nodal status was further stratified by size and histologic grade (Table 11). There
remained a significant difference for mean survival between node negative and
node positive patients for tumors -< 4 and tumors greater than 4 cm.
The combination of differentiation and nodal status demonstrated differences in
survival for node negative patients. For patients with negative regional lymph
nodes, well differentiated status predicted for improved survival when compared to
less well differentiated status (32.5 months versus 14.4 months, respectively
p< .05). In contrast, the finding of positive lymph nodes was more important than
differentiation status for survival. There was no difference in survival between well
differentiated and less well differentiated positive node patients.
In summary, there remained a significant difference in overall survival between
node negative patients and node positive patients in all groups. Most importantly, a
subset of patients with well differentiated tumors and regional lymph nodes free of
disease demonstrated the longest survival in this series of 32.5 months from the
time of resection. This differed from a subset of patients with less well differen-
tiated, node free disease who had a mean survival of 14.4 months from resection.
No stratification of node positive patients predicted for improved survival within
this poor prognosis group of patients.
Table 10 Overall survival after pancreas resection for pancreatic carcinoma. Overall survival was analyzed
as a function of both local spread and the regional lymph node status
Survival from Operation (months)
Overall Mean Survival 14.3
Local Spread T1 24.5 ---I *--] T2 8.3
T3 7.8
Regional Lymph Nodes NO 23.5 ** N1 7.4
*(p <0.05); **(p <0.01).PANCREATIC CANCER 9
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Figure 2 Actuarial survival as a function of regional lymph node status. Negative regional lymph nodes
-El-Positive regional lymph nodes ,
Table 11 Survival by regional lymph node status as a function of tumor size and grade. Tumors were
stratified by size, differentiation, and nodal status and analyzed for overall survival
Regional Lymph Nodes
Overall Survival (months)
Negative (NO) Positive (N1)
Size
<4cm 28.2 5.9
>4cm 15.0 "--I ns 9.1 "’l ns
Grade
Well differentiated 32.5 ---1, 8.6 ----1 ns Less well differentiated 14.4 6.8
(p <0.05) for all node negative vs node positive groups" *(p <0.05).
DISCUSSION
A number of recent studies have demonstrated a trend for improved survival after
curative resection for carcinoma of the pancreas with some institutions having
reported five year actuarial survival rates of 20%6’1819. In addition, a well organized
prospectively randomized trial from the Gastrointestinal Tumor Study Group
(GITSG) has demonstrated that combination radiotherapy and chemotherapy may10 S. T. BROWER ET AL.
double mean survival in selected patients after resection for carcinoma of the head
of the pancreas2.
Most of these studies have attempted to identify prognostic factors relevant in
predicting long term survival. Many factors have been identified as important
predictors of improved surgical outcome3’7’z9. Some of these include improved
technical aspects for the performance of pancreatectomy as well as regionalization
and specialization for major pancreatic resection. The results of our study predict
that this improvement should be interpreted within the context of clearly defined
histopathological parameters of the tumor that may influence long term survival. In
our series, both the degree of local spread and regional lymph node metastases had
a significant effect on survival after operation.
We have shown a median overall survival for the entire group of resected cancer
patients of 14.3 months and actuarial survival of 17.6% at 36 months. These results
seem to compare favorably with other large series of reported cases of resectable
carcinoma of the pancreas6"2122. This survival is the result of a number of complex
factors the most important of which is the biological aggressiveness of the tumor as
measured by the pathological stage.
Other recognized important factors include delay to presentation, perioperative
mortality, and other more recently recognized independent prognostic factors such
as blood transfusions67’17’22-23. We have shown, however, that with careful subset
analysis, groups may exist that exhibit satisfactory long term results. For example
we have shown that tumors confined to the pancreas exhibit from 1 1/2 to 4 fold
increase in the median overall survival when compared to locally infiltrating or
regionally advanced pancreas cancer (see Table 10). More importantly the absence
of regional lymph nodes confers a three-fold increased survival advantage over
node positive patients, with the median overall survival for patients with negative
lymph nodes approximating 21 months (see Figure 2). A smaller tumor size and
negative lymph nodes does not yield an increased survival advantage over node
negative tumors > 4cm. Conversely, the association of a well differentiated tumor
and negative lymph nodes confers a statistically significant survival advantage
compared to patients with moderately or poorly differentiated cancers and negative
lymph nodes (26.8 versus 16.7 months, respectively). Unfortunately, we have not
recognized any subset of node positive patients in which either size, differentiation,
or location of tumor confers a survival benefit.
It has been previously recognized that most early carcinomas of the pancreas are
located in the pancreatic head12’24. In our series, 88% of the T tumors were small
tumors located in the head of the pancreas. However, 2/3 of these small pancreatic
head lesions are associated with metastatic carcinoma. Furthermore, although the
chance for a tumor to be localized (T) is greater in lesions in the head than for
other regions, only the minority of the resected pancreatic head carcinomas in our
series were limited to the pancreas at the time of operation.
Similarly, when examining T2 lesions, small tumor size (< 4cm) did not accu-
rately predict confined local spread or nodal status. Large tumors > 4 cm as a group
were characterized by a greater degree of local spread and regional lymph node
involvement. This frequent spread of small tumors is reflected by the absence of
increased survival for small tumors compared to large tumors when one stratifies
the patients by similar nodal status.
The degree of histologic differentiation seems to favorably effect the degree of
local spread of the primary in our series. Patients with well differentiated tumors
were also more likely to be free of lymph node metastases. These effects may havePANCREATIC CANCER 11
contributed to the reasonable survival enjoyed by the subset of patients with well
differentiated node free disease demonstrated to be significantly different from a
less well differentiated node free counterpart.
Our results of 31% actuarial survival at 36 months for node negative patients is
similar to other recent studies reporting increased survival rates for this disease. It
should be emphasized that in our series, the absence of regional lymph nodes was
not a minor percentage of patients but involved 16 of 35 patients or 45% of the
entire group.
A number of characteristics of the cumor were significant in predicting long term
survival. Of particular note was the absence of lymph nodes, well differentiated
status of the primary tumor, and degree of local spread (T versus T2, T3). Size did
not seem to significantly impact on overall survival. When these factors were
evaluated for multivariant analysis, the presence or absence of lymph node
metastases was the single most important factor in determining improved survival.
Prior studies have examined survival rates following resection of pancreas
carcinoma and have quoted survival rates less than 10%. These studies have not
necessarily examined subsets of patients with the required vigorous attention to
histopathological detail that more recent studies and our present study have
utilized. As a result of the poor results, there has been little enthusiasm for further
improvement with adjuvant therapy25. More importantly it has not been easy to
identify subsets of patients that would benefit from the possibility of radiation
therapy and combination chemotherapy. We have demonstrated that patients
without lymph nodes, tumor confined to the pancreas, and well differentiated
status may have a survival status that would benefit from adjuvant therapy. There is
little information available regarding adjuvant treatment after surgical resection for
cancer of the pancreas. A study of the Gastrointestinal Tumor Study Group,
although based on few patient numbers, suggested that there may be an advantage
to adding 5FU plus external beam radiation in some patients with a two year
survival improvement of 43% versus 18% for the control patients who received
surgery alone. The results of our study and others showing improved survival
should further encourage the development of new combination multidisciplinary
therapies such as radiosensitization, chemohormonal synchronization, and anti-
body targeted direct adjuvant therapies including growth factor and signal trans-
duction protein inhibitors for pancreas carcinoma that have been shown to have
some benefit in vitro26.
In conclusion, although the overall results for the majority of patients after
resection for pancreas carcinoma are poor we have shown in defined subsets that a
reasonable survival may be achieved. The size of the tumor is often a misleading
guide to the degree of local spread or nodal status. Histologic grade of the primary
tumor, substantiated by DNA synthetic rates,
27 may be more helpful in predicting
localized disease and improved survival after attempted curative resection for
carcinoma of the pancreas. For the node negative group of patients survival rates
may be similar to other neoplasms within the gastrointestinal tract such as colon
cancer who recently have benefited greatly from successful adjuvant therapy.
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INVITED COMMENTARY
The prognosis of pancreatic cancer is so poor that any attempt to present data on
the factors that influence survival is welcome. Dr Brower and colleagues show that
certain histological features of the tumour affect long-term survival, although this
discovery is not entirely new.
The authors report a good correlation between prognosis and three histopatholo-
gical factors: extent of local growth, state of regional lymph nodes and degree of
cellular differentiation. Tumour size did not accurately predict prognosis, although
patients with bulky tumours did badly because these were generally associated with
local invasion and lymph node metastasis.
Previous workers have considered this problem. Tumour size alone does not
appear to affect prognosis1. Small tumours (< 2cm) can still present with advanced
local disease or distant spread at the time of diagnosis. In one series 71 per cent of
patients with carcinomas < 2cm had already reached stage II-IV by the time of
pancreatic resection
2 and in another series 560/0 3. Nevertheless, small cancers
generally carry higher rates of resectability and better survival4-6, possibly because
they are diagnosed at an earlier stage or are less biologically aggressive.
This histological characteristics of the resection specimen have also been the
object of study. Malignant infiltration of the pancreatic capsule, proximity of the
tumour to lymphatic or blood vessels, round cell infiltration at the tumour margin
and epithelial atypia in the pancreatic ducts away from the tumour are all factors
that have been associated with a poor prognosis7. The location of a tumour in the
pancreatic body and tail or an eccentric site within the head (far from the duct) are
also unfavourable factors8. To obtain these data, endoscopic ultrasonography can
make a valuable contribution to preoperative staging9, supplementing conventional
abdominal ultrasound and CT Scan. Another crucial factor in determining the
outcome is the presence of tumour-free margins in the resected part1’11.
Regional lymph node involvement has received a good deal of attention. As
Brower and colleagues report, lymph node metastasis usually conveys a very poor
prognosis3’12-14, although other reports do not confirm such a clear correlation’1.
Likewise, poorly differentiated tumours generally do worse, although some studies
have not found this feature relevant15.
All these histopathological factors reflect the tumour’s biological aggressiveness,
and this may better be evaluated using modern techniques such as analysis of
nuclear DNA content. Some studies of pancreatic cancer have observed a good
correlation between resectability/survival and certain characteristics of nuclear
DNA6’17. Thus cancers with tumour stemlines in the diploid region and with fewer
than 6% S phase cells have a more favourable prognosis. Quantitative studies of
DNA content may well provide further important information for planning treat-
ment.
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